Aglatimagene besadenovec

Drug Profile

Aglatimagene besadenovec

Alternative Names: Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy; AdV-Tk; AdV-tk therapy - Advantagene; ADV/HSV-tk; CanAtak; Cancer gene therapy - Advantagene; Gene Mediated Cytotoxic Immunotherapy; GliAtak; HSV-vectored thymidine kinase; OncAtak; PancAtak; ProstAtak; TKR therapy - Advantagene; Virafir

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advantagene
  • Developer Advantagene; Methodist Healthcare Ministries of South Texas
  • Class Antineoplastics; Gene therapies; Gene-directed enzyme-prodrug therapies
  • Mechanism of Action Thymidine kinase expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Breast cancer; Glioma; Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Malignant pleural effusion; Ovarian cancer
  • Preclinical Glioblastoma; Mesothelioma; Oesophageal cancer

Most Recent Events

  • 01 Jul 2017 Phase-II clinical trials in Breast cancer (Metastatic disease, Late-stage disease) in USA (Intratumoural) (NCT01913106)
  • 01 Jul 2017 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease) in USA (Intratumoural) (NCT01913106)
  • 24 Apr 2017 Phase-I clinical trials in Non-small cell lung cancer (Neoadjuvant therapy) in USA (Intratumoural) (NCT03131037)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top